SNYNF - Sanofi
About Sanofi (https://www.sanofi.com)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Belen Garijo Lopez | Chief Executive Officer & Director | 1960 | $4,722,547 EUR |
| Emmanuel Frenehard | Executive VP & Chief Digital Officer | 1972 | – |
| Erik Wallström | Head of Therapeutic Area - Neurology Development | – | – |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | – | – |
| François-Xavier Roger | Executive Vice President & Chief Financial Officer | 1962 | – |
| Houman Ashrafian | Executive VP & Head of Research & Development | 1975 | – |
| Jamie Haney | Executive Vice President & General Counsel | – | – |
| Karin Knobe | TA Head of Rare Diseases & Rare Blood Disorders Development | – | – |
| Madeleine Roach | Executive Vice President & Head of Business Operations | 1984 | – |
| Michael Quigley | Chief Scientific Officer & Head of Research | – | – |
| Olivier Charmeil | Executive Vice President of General Medicines | 1963 | – |
| Olivier Klaric | Senior Vice President of Financing & Treasury | 1962 | – |
| Pablo Sardi | TA Head of Rare & Neurologic Diseases Research | – | – |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 1957 | – |
| Roy Papatheodorou | Executive Vice President & General Counsel | 1978 | – |
| Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 1974 | – |
| Thomas Triomphe | Executive Vice President of Vaccines | 1974 | – |
| Veronique Jaillet | Executive VP & Interim Chief People Officer | – | – |